August 25, 2022 11:01 AM EDT
News Briefing

Bei­jing CRO ex­pands agree­ment with Mer­ck KGaA; Ear­ly-stage ven­ture firm clos­es its first fund

Lei Lei Wu

News Reporter

On Thurs­day morn­ing, Bei­jing-based CRO Bio­cy­to­gen an­nounced that it has for­mal­ized and ex­pand­ed its April agree­ment with Mer­ck KGaA fol­low­ing an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Why Re­gen­eron is buy­ing 23andMe

Pfiz­er joins PD-1xVEGF race with $1.25B up­front to Chi­nese biotech 3SBio

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times